Kuromanin

Kuromanin

SCHEMBL289710

OC[C@H]1OC(Oc2cc3c(O)cc(O)cc3[o+]c2-c2ccc(O)c(O)c2)[C@H](O)[C@@H](O)[C@H]1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CD38 P28907 2/20 1.00
DPP4 P27487 2/20 1.00
F2 P00734 2/20 0.89
KDM4E B2RXH2 4/20 0.52
GAA P10253 4/20 0.52
AKR1B1 P15121 4/20 0.52
MAPT P10636 3/20 0.52
POLB P06746 2/20 0.52
P4HB P07237 2/20 0.52
EPHX2 P34913 2/20 0.52
ADRA2C P18825 1/20 0.52
NOX4 Q9NPH5 1/20 0.52
CA12 O43570 1/20 0.52
KDM1A O60341 1/20 0.52
SLCO2B1 O94956 1/20 0.52
CA2 P00918 1/20 0.52
ALPL P05186 1/20 0.52
HMGB1 P09429 1/20 0.52
ALPI P09923 1/20 0.52
PKM P14618 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Kuromanin SCHEMBL9234361 1.00 CD38 (1.00) CD38DPP4F2KDM4EGAA
Kuromanin SCHEMBL30548128 1.00 CD38 (1.00) CD38DPP4F2KDM4EGAA
Kuromanin SCHEMBL29349861 1.00 CD38 (1.00) CD38DPP4F2KDM4EGAA
Kuromanin SCHEMBL1101355 1.00 CD38 (1.00) CD38DPP4F2KDM4EGAA
Kuromanin SCHEMBL8818180 1.00 CD38 (1.00) CD38DPP4F2KDM4EGAA
Kuromanin SCHEMBL409593 1.00 CD38 (1.00) CD38DPP4F2KDM4EGAA
Kuromanin SCHEMBL1097555 1.00 CD38 (1.00) CD38DPP4F2KDM4EGAA
Kuromanin SCHEMBL288591 1.00 CD38 (1.00) CD38DPP4F2KDM4EGAA
Kuromanin SCHEMBL1096430 1.00 CD38 (1.00) CD38DPP4F2KDM4EGAA
Kuromanin SCHEMBL440823 0.99 DPP4 (0.98) CD38DPP4F2KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 674 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122005539-A Application of anthocyanin in preparation of product for relieving nonalcoholic fatty liver disease by regulating CCL3-FABP4 signal axis 辽宁大学 2026-05-12 CN claimed
WO-2026087503-A1 NON-THERAPEUTIC USE OF ARONIA EXTRACT FOR ENHANCING EXECUTIVE FUNCTION BIOACTOR BV (NL) 2026-04-30 WO claimed
US-12507720-B2 Use of anthocyanin-anionic polysaccharide complex for preventing or treating influenza virus A infection JBKLAB CO., LTD. (KR) 2025-12-30 US claimed
US-20250386844-A1 HEALTHY SWEETENERS COMPRISING ANTIOXIDANTS Apple Sugar LLC (US) 2025-12-25 US claimed
EP-4626258-A1 NON-THERAPEUTIC USE OF AN ARONIA BERRY EXTRACT BioActor B.V. (NL) 2025-10-08 EP claimed
US-20250213634-A1 PREPARATIONS CONTAINING ANTHOCYANINS FOR USE IN THE INFLUENCE OF CARDIOVASCULAR CONDITIONS MEDPALETT AS (NO) 2025-07-03 US claimed
CN-120154656-A Extract with osteoarthritis prevention and treatment effect and application thereof 青岛大学 2025-06-17 CN claimed
CN-119950578-A Application of mulberry total polyphenol extract in preparation of products for promoting bone formation 青岛大学 2025-05-09 CN claimed
CN-119874790-A Separation preparation method and application of cyanidin-3-O-galactoside 浙江大学中原研究院 2025-04-25 CN claimed
CN-119867072-A Phagostimulant composition for codling moth larvae and application thereof 广东省科学院动物研究所 2025-04-25 CN claimed
WO-2005077176-A1 ANTHOCYANIN COMPOUNDS AND METHODS OF USE THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2005-08-25 WO claimed
US-20050037095-A1 Compositions enriched in anthocyanins PHENOLICS, LLC 2005-02-17 US claimed
EP-1328282-A4 EFFICIENT METHOD FOR PRODUCING COMPOSITIONS ENRICHED IN ANTHOCYANINS HAUSER INC (US) 2004-02-11 EP claimed
EP-1328282-A1 EFFICIENT METHOD FOR PRODUCING COMPOSITIONS ENRICHED IN ANTHOCYANINS Hauser, Inc. (US) 2003-07-23 EP claimed
US-20020055471-A1 Efficient method for producing compositions enriched in anthocyanins PHENOLICS, LLC 2002-05-09 US claimed
US-20020054924-A1 Novel compositions derived from cranberry and grapefruit and therapeutic uses therefor LEAHY MARGARET M (US) 2002-05-09 US claimed
WO-2002024212-A1 CHOLESTEROL IN BLOOD-LOWERING COMPOSITION AND ITS COMPLEX, AND METHOD FOR PREPARING THEM ULTIMATE LIFE TECHNOLOGY CO., LTD. (KR) 2002-03-28 WO claimed
WO-2002017945-A1 EFFICIENT METHOD FOR PRODUCING COMPOSITIONS ENRICHED IN ANTHOCYANINS HAUSER, INC. (US) 2002-03-07 WO claimed
WO-2002017732-A2 EFFICIENT METHOD FOR PRODUCING COMPOSITIONS ENRICHED IN ANTHOCYANINS TEMPESTA, MICHAEL, S. 2002-03-07 WO claimed
WO-2001080870-A2 COMPOSITIONS DERIVED FROM CRANBERRY AND GRAPEFRUIT AND THERAPEUTIC USES THEREFOR OCEAN SPRAY CRANBERRIES, INC. (US) 2001-11-01 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12507720-B2 Use of anthocyanin-anionic polysaccharide complex for preventing or treating influenza virus A infection FUT6, ALG1, PIGS CD38 336/4885DPP4 179/4885F2 2387/4885
US-20250386844-A1 HEALTHY SWEETENERS COMPRISING ANTIOXIDANTS GCK, HK2, GCG CD38 2105/4885DPP4 189/4885F2 852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.